At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 28 enrolled
Drug / intervention
Enstilar +2 moredrug
Likely dose
Otezla 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis
In Brief
A Phase 4 clinical trial evaluating Enstilar, Vehicle, and 1 other intervention for Plaque Psoriasis. Completed, enrolled 28 participants across 4 sites.
Detailed Summary
This study seeks to show whether there is a benefit of prescribing Enstilar with Otezla in the treatment of patients with moderate plaque type psoriasis. Subjects will be randomized to study treatment at a 1:1 ratio of Otezla plus Enstilar foam versus Otezla plus vehicle foam.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
Enrollment StartSep 2017
First PostedFeb 2018
Primary CompletionOct 2018
Study CompletionOct 2018
TodayJul 2026
First PostedFeb 22, 2018
Enrollment StartSep 18, 2017
Primary CompletionOct 1, 2018
Study CompletionOct 22, 2018
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 8.4 years ago
Interventions
Enstilardrug
Enstilar foam applied to affected areas daily
Vehicledrug
vehicle foam applied to affected areas once daily
Otezladrug
Otezla 30mg